ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following investor conferences in November 2021:

• Stifel’s 2021 Virtual Healthcare ConferenceMonday, November 15, 202110:40 am Eastern Time

• Jefferies London Healthcare ConferenceThursday, November 18, 20218:00 am GMT

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™).   For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Will BrownChief Financial OfficerPhone:   240-654-1450wbrown@altimmune.com